Infectious endophthalmitis: case reportIn a retrospective consecutive case series performed at a hospital in Pakistan between August 2018 and January 2019, involving 2734 patients treated with bevacizumab between August 2015 and July 2018, a 65-year-old woman was described; she developed infectious endophthalmitis following treatment with bevacizumab.The woman, who had diabetes, presented for the treatment of diabetic macular oedema. She was initially administered proxymetacaine [Alcaine; proparacaine hydrochloride] and moxifoxacin [Vigamox]. Scrubbing with povidone iodine followed. Thereafter, lidocaine [lignocaine] and povidone were applied over the conjunctiva at the site of injection. She subsequently received an intravitreal injection of bevacizumab [Avastin] 1.25 mg/0.05mL in her left eye, for the treatment of diabetic macular oedema. On day 3 after receiving the injection, she presented with complaints of sudden-onset pain, loss of vision and redness. Examination revealed a visual acuity of light projection. She was also found to have an anterior chamber reaction in the form of a 3mm hypopyon, with poor fundal view and extensive fibrin. A diagnosis of infectious endophthalmitis secondary to bevacizumab was made.The woman underwent pars plana vitrectomy; she also received vancomycin and ceftazidime. A vitreous culture report did not reveal any growth. During 3-month follow-up, her visual acuity improved to 0.1 logarithm of the minimum angle of resolution.